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Abstract
Background: Myocardial cavitation-enabled therapy (MCET) has been proposed as a means to achieve minimally
invasive myocardial reduction using ultrasound to produce scattered microlesions by cavitating contrast agent
microbubbles.
Methods: Rats were treated using burst mode focused ultrasound at 1.5 MHz center frequency and varying envelope
and pressure amplitudes. Evans blue staining indicated lethal cardiomyocytic injury. A previously developed quantitative
scheme, evaluating the histologic treatment results, provides an insightful analysis for MCET treatment parameters. Such
include ultrasound exposure amplitude and pulse modulation, contrast agent dose, and infusion rate.
Results: The quantitative method overcomes the limitation of visual scoring and works for a large dynamic range of
treatment impact. Macrolesions are generated as an accumulation of probability driven microlesion formations.
Macrolesions grow radially with radii from 0.1 to 1.6 mm as the ultrasound exposure amplitude (peak negative)
increases from 2 to 4 MPa. To shorten treatment time, a swept beam was investigated and found to generate an
acceptable macrolesion volume of about 40 μL for a single beam position.
Conclusions: Ultrasound parameters and administration of microbubbles directly influence lesion characteristics such
as microlesion density and macrolesion dimension. For lesion generation planning, control of MCET is crucial, especially
when targeting larger pre-clinical models.
Keywords: Cavitation microlesions, Hypertrophic cardiomyopathy, Myocardial macrolesion, Therapeutic ultrasound,
Quantitative therapy analysis
Introduction
Hypertrophic cardiomyopathy (HCM) is a common gen-
etic cardiovascular disease, which is usually clinically
recognized by a maximal left ventricular wall thickness
greater than 15 mm [1]. This globally prevalent disease,
reported in about 0.2 % (i.e., 1:500) of the general popu-
lation, is the most frequent cause of sudden death in
young people and can lead to functional disability from
heart failure and stroke [2].
The traditional treatment for HCM to reduce myocar-
dium is septal myectomy. This surgical method removes
septal hypertrophy, which possibly leads to perturbation
of mitral valve leaflets [3]. An innovative therapeutic
scheme, named myocardial cavitation-enabled therapy
(MCET), has been proposed as a means to achieve min-
imally invasive myocardial reduction by cavitating con-
trast agent microbubbles with ultrasound to produce a
fractional macrolesion containing sparse and histologi-
cally definable microlesions [4]. There are several ways
of controlling cavitation here. Cavitation is enabled by
the injection of ultrasound contrast agents. These will
enable cavitation only in the focal region of the trans-
ducer and thus only there lead to microlesion formation
in the myocardium. Second, ultrasound cavitation is
dependent on sound pressure amplitude. In vivo experi-
ments reveal that cavitation-induced lesions take place
at peak rarefactional pressures larger than 2 MPa as
obtained under free field conditions. In this case, ECG is
monitored for premature complexes. It has been seen
that the occurrence of premature complexes is directly
correlated with cavitation events [5].
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As a potential tissue reduction therapy, MCET avoids
open-chest surgery and is hypothesized to allow healing
with minimal scar formation, resulting in shrinkage of the
cardiac treatment volume. This ultrasound microbubble-
enabled method additionally provides the possibility of
guiding and monitoring via quantifying feedback from
the microbubble emissions.
To optimize MCET ultrasound parameters and admin-
istration of microbubble settings, assessment of the
therapeutic effect is needed to assist parameter adjust-
ment. Efforts in computerized analysis have been made
to aid diagnostics and therapy for being fast, objective,
and quantitative. Methods have been developed for
computed tomographic angiography for the purposes of
detecting heart diseases [6, 7] and for quantification of
coronary arterial stenosis [8]. Automatic detection of pul-
monary embolism has also been used in CT angiography
[9, 10]. Quantitative ultrasound has been employed in
diagnosis of osteoporosis [11], as well as in at-risk preg-
nancies with three-dimensional sonographic measurement
of blood volume flow in umbilical cords [12]. Three-
dimensional high-frequency ultrasound data also has been
processed to offer a quantitative evaluation of cancerous
lymph nodes at the microscopic level [13].
For MCET, a quantitative method for assessing the
distribution and total accumulation of myocardial necro-
sis based on Evans blue-stained cells in the tissue hist-
ology slices was developed previously [14] and is used in
this study. This paper investigates the tuning of various
parameters involved in MCET and paves the way for
pre-clinical treatment planning of myocardial lesion cre-
ation and properties thereof, in a quantitative manner.
One important and practical aspect of MCET is man-
aging the buildup of microlesions and macrolesions to
achieve a desired amount of myocardium reduction in
larger pre-clinical models as well as, ultimately, in the
clinic. Acoustic pressure amplitude, contrast dose, and
treatment duration are adjustable variables. The para-
metric exploration of various conditions will assist in the
search for feasible treatment conditions that allow for
fast lesion creation with a 15–20 % microlesion density
and a large axial and lateral dimension. Another desir-
able factor for practical clinical implementation is the
treatment efficiency. Instead of treating a single focal
spot as done in our previous study [4], a scanned beam
would allow for a more rapid accumulation of lesions in
a larger target treatment volume.
Our method of computer-aided histology analysis was
developed using relatively high exposure parameters to
reflect therapeutic treatment conditions [12]. This pro-
vided a means to reconstruct the tissue volume contain-
ing microlesions and their distribution, which can then
be integrated to yield the potential fraction of tissue
reduction. For validation, a visual scoring method was
used in tandem, in which lethally injured cells indicated
by fluorescent staining in frozen sections were counted.
The visual method has been the gold standard for quan-
tifying cell death by counting the absolute number of
stained cells. However, when the number of stained cells
becomes large, as for treatment (rather than exploring
bioeffects), the visual method becomes a qualitative
scoring method, which was suspected to yield inaccurate
results for the validation for the computer-aided method.
The purpose of this study was to analyze several exposure
groups, which had reduced, sub-therapeutic treatment




In order to make MCET amenable to clinical translation,
the evaluation of B-mode echogenicity (more generally
backscatter), physiological responses, i.e., premature com-
plexes and visual scoring [15] is employed. For this study,
tissue samples were collected and prepared for histological
evaluation. Specifically, these samples underwent quanti-
tative analyses aimed to assist the treatment planning.
In vivo animal procedures were conducted on 50 male
Sprague-Dawley rats (Charles River, Wilmington, MA,
USA) including 5 sham rats weighing 352 ± 30 g. Approval
and guidance of all animal work was done by the Univer-
sity Committee on Use and Care of Animals. All rats in
the treated group were injected with Definity® (Lantheus
Medical Imaging, Inc., N. Billerica, MA) at a rate of 5 or
12.5 μL/kg/min. Microbubbles suspended and diluted in
sterile saline were infused via a tail vein or jugular vein
catheter (gauge #24) starting 15 s before ultrasound ex-
posure and concluding with the end of exposure. MCET
was performed with ultrasound bursts of 5-cycle pulses at
a center frequency of 1.5 MHz and a pulse repetition
frequency of 4 kHz. The ultrasound exposure system con-
sisted of a function generator for generating a pulse train
(model 3314A function generator, Hewlett Packard Co.,
Palo Alto CA), an arbitrary waveform generator for ampli-
tude modulation of the pulse train (model 33220A,
Agilent Technologies, Loveland CO), a power amplifier
(A-500, Electronic Navigation Industries, Rochester NY),
and a 1.5-MHz single element therapy transducer
(Panametrics A3464, Olympus, Waltham, MA). The ther-
apy transducer was a standard single-element focused
transducer, with a 1.9-cm diameter and 3.8-cm focal
length. The treatment was targeted with the aid of diag-
nostic ultrasound imaging (GE Vivid 7 with S-10 phased
array, GE Healthcare, Jupiter FL, USA) operated at
10 MHz with a 5-cm focal depth, as previously described
[15]. The setup scheme as illustrated in Fig. 1 provided
targeting of the therapy beam and for low-power imaging
of the heart during exposure. The imaging array and
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therapeutic transducer were fixed at a 37° angle such that
the acoustic axis of the therapy transducer is parallel with
one image line of the sector array. This image line was
identified in a water tank using a line target and marked
on the screen of the ultrasound scanner. Then, this image
line was used to evaluate acoustic access to the left ven-
tricular wall. Subsequently, the transducer/probe gantry
was translated such that the therapy transducer beam
aimed along the same fixed path as the image line identi-
fied in the image to pass through the window between the
ribs (vertical axis) and between the sternum and the left
lung. Burst emissions were triggered from the ECG signal
at every four heartbeats end-systole. Prior to ultrasound
exposure, all rats were injected with Evans blue, a reliable
histological stain for lethal injury of cardiomyocytes [15].
The study was conducted with groups of five rats each
and given letter designations to identify the specific set
of conditions in each group. Groups A to J were de-
signed specifically to test treatment effects for different
parameters, as listed in Table 1. Except for groups G and
H, all rats were exposed to ultrasound with a maximum
rarefactional pressure amplitude (PRPA) of 4 MPa. The
pulses in the center of the focal region were mea-
sured in a water bath using a calibrated hydrophone
with a 0.2-mm diameter aperture (model HMA-0200,
Onda Corp., Sunnyvale, CA) to acquire the point spread
function and the electro-acoustic transfer function. Com-
parison of groups A and B tested the influence of catheter
placement, with the jugular vein giving a central and lar-
ger vein access than the tail vein. Groups B and C were
compared to test the effect of aiming ultrasound near the
ribs. Those two comparisons were performed intentionally
to test experimental perturbations.
Groups B and D compared the results of treatment
using square versus Gaussian pulse train modulations of
the acoustic pressure. The single element transducer de-
livered a Gaussian envelope pulse train, such that the
full-width half maximum of the Gaussian modulation
was 2 ms. This modulation scheme was to simulate an
exposure that would be experienced by contrast agent in
the presence of a sweeping ultrasound beam, as found in
a diagnostic imaging setup [16]. To reduce treatment
times for larger treatment, volumes such a beam could
be implemented as a sweeping therapy beam and is thus
included in the tested exposure conditions. Note that
only the pulse train envelope is Gaussian modulated.
Each individual pulse is a constant amplitude 5-cycle
tone burst (see Fig. 2). The amplitude modulation was
set to give zero exposure unless a modulation envelope
signal was triggered. The envelope signal was either a
2-ms square pulse with a constant amplitude of
4 MPa PRPA or a Gaussian modulation function that
Fig. 1 Schematic illustration (top view and side view) of the experimental
setup. The imaging array and therapeutic transducer were fixed at a 37°
angle so the acoustic axis of the therapy transducer was parallel with a
specific image line of the sector array. This image line was
identified in a water tank using a line target and marked on the screen
of the ultrasound scanner. This image line was then used to warrant the
acoustic access to the left ventricular wall. Subsequently, the transducer/
probe gantry was translated so the therapy transducer beam followed
the same path as for the previously identified image line
Table 1 Table of sets of conditions used for respective groups
of rats, with a cohort of five animals each





Modulation Infusion rate Treatment
duration
A Tail 4 MPa Square 5 μL/kg/min 5 min
B Jugular 4 MPa Square 5 μL/kg/min 5 min
C Jugular 4 MPa Square 5 μL/kg/min 5 min
D Jugular 4 MPa Gaussian 5 μL/kg/min 5 min
E Jugular 4 MPa Gaussian 12.5 μL/kg/min 2 min
G Tail 2 MPa Gaussian 5 μL/kg/min 5 min
H Tail 2.8 MPa Gaussian 5 μL/kg/min 5 min
I Tail 4 MPa Gaussian 5 μL/kg/min 100 s
J Tail 4 MPa Gaussian 5 μL/kg/min 30 s
Group F acted as a sham and calibration group, as described in the text
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produced a 2-ms pulse with amplitudes greater than
2 MPa PRPA. The Gaussian modulation was designed
to emulate a scanned ultrasound beam from a clinical
ultrasound scanner, with approximately 56 frames per
second (fps).
Different contrast agent dose rates were tested by com-
paring groups D and E. The previous rate was 5 μL/kg/min,
representing the recommended dose for diagnostic applica-
tions [4]. A higher infusion rate of 12.5 μL/kg/min was
tested for the possibility of using a higher dose in thera-
peutic applications, which may reduce treatment durations.
Comparison between groups G, H, and D evaluated
the dependence of lesion formation on acoustic pressure.
The three groups were respectively exposed to ultra-
sound fields of 2, 2.8, and 4 MPa PRPA. Groups J, I, and
D, on the other hand, evaluated microlesion accumula-
tion by varying the treatment duration, i.e., adjusting the
contrast infusion duration. Groups G, H, I, and J were
specifically treated with sub-therapeutic parameters with
reduced treatment impact on cell survival. Correlation
between acoustic pressure, treatment duration, and in-
duced microlesion density was intended to establish
some dynamic range for microlesion induction.
Finally, group F was a sham and calibration control
group, in which each rat received the full 4 MPa therapy
exposure before the contrast agent infusion started.
Results in groups are presented in boxplots. For each
box, the central mark is the median, the edges of the
box are the 25th and 75th percentiles, the whiskers
extend to the most extreme data points not considered
outliers, and outliers are plotted individually. The nor-
mal range was defined as q3 + 1.5 (q3 − q1) or smaller
than q1 − 1.5 (q3 − q1), where q1 and q3 are the 25th and
75th percentiles, respectively.
Cardiomyocyte scoring
Rat hearts were harvested and scored 1 day after expos-
ure as described in previous work [15]. Briefly, up to 40
10-μm-thick frozen sections were made from the treated
volume in each heart. A quantitative method for asses-
sing the distribution and total accumulation of myocar-
dial necrosis is based on Evans blue staining and was
developed previously [14]. Microlesions were identified
by fluorescence microscopy and photographs of each
section. Image registration was then performed to digit-
ally stack the frozen sections in 3D and to reconstruct a
model of the heart morphology in the entire sampled
region showing the three-dimensional distribution of
microlesions. The microlesion fraction of the tissue
within the focal zone was calculated to estimate the
potential fractional volume of tissue reduction that was
achieved. Quantitative results were characterized in terms
of microlesion volume, macrolesion volume, microlesion
lesion density, and dimensions of the radially symmetric
approximated macrolesion.
In addition to the computer-aided assessment, trad-
itional visual scoring was used to evaluate myocardial
necrosis qualitatively by visual identification and quanti-
tatively by scoring of Evans blue-stained cells using
fluorescence microscopy [15]. Automatic scores were
obtained from dividing the geometric microlesion vol-
ume by a constant conversion factor acquired from a
geometry-based cardiomyocyte model [14].
Therapeutic field simulation
The acoustic field, assuming a water path, for the
employed single-element therapeutic transducer was sim-
ulated in FIELD II [17], a widely used ultrasound simula-
tion program. A 1.9-cm diameter concave single-element
transducer with 3.8 cm focus excited at 1.5 MHz with a 5-
cycle burst was modeled. Two successive bursts 250 μs
apart (4 kHz PRF) were significantly larger than the 3-μs
pulse train length. Thus, they were considered to have no
Fig. 2 Employed electric pulse train excitations. Circles in square
modulation (a) and Gaussian modulation (b) pulse trains indicate
the employed negative pressure amplitudes. Note that each spark is
a 5-cycle 1.5 MHz tone burst
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interference on each other’s acoustic field. Figure 3a shows
a normalized field reflecting the maximum exposed
pressure during one burst. The effective region of sound
pressures with amplitudes above the acoustic pressure
threshold of 2 MPa is indicated in Fig. 3b. By revolving
this shown region along the lateral (x = 0 mm) axis, the
effective volume, denoted as an axisymmetric rotational
model, was calculated. This simulation intended to associ-
ate in situ acoustic field with the formed lesion.
Results
Quantitative computer-guided lesion analysis
The previous study [4] was limited by a low dynamic
range with respect to the number of induced lesions.
Current results span a large range of number of lesions
per area on histology, which therefore allows for a more
critical evaluation of the performance comparison be-
tween visual and automatic scoring. Data presented in
this study reach to tens of thousands of lesions, a range
that is difficult to assess quantitatively by traditional vis-
ual scoring. Figure 4 shows visual scores plotted versus
auto scores (obtained from computer-aided algorithm)
for all groups listed in Table 1. The data can be seg-
mented in two regions: low counts ranging from 0 to
15,000 and high counts from 15,000 to 80,000 (both
with respect to the auto score), respectively. A linear
least square fit of the form y = a1·x, was performed for
the low lesion count segment and is shown in red and
extended as blue in Fig. 4. Another linear least square
fit, now of the form y = a2·x + b, was performed for the
high lesion count segment and is shown in red in Fig. 4.
Best-fit coefficients were found as: a1 = 1.52, a2 = 0.19
and b = 15,216, with a1 greater than 1 would mean that
visual scoring counted more cells, a2 being so low shows
that visual scoring counted groups of cells as one. This
result clearly showed the “saturation” effect of the visual
scoring method for high cell counts.
Acoustic pressure dependence
Macrolesion volumes
Macrolesion dimensions are in part dictated by the
therapy beam geometry as illustrated in Fig. 5. Lesion
lengths (axial) and lesion diameters (lateral and eleva-
tional) are determined by the point spread function of
the therapy transducer and the acoustic pressure of the
transmitted wave. In other words, the volumetric region
of the acoustic wave that bears pressure amplitudes
above the pressure pL required for lesion formation, will
contribute to the therapy. This volumetric region grows
as the pressure amplitude at the focus grows, and thus,
larger acoustic pressures yield larger lesion count.
Macrolesion dimensions are also dictated by the spatial
availability of cells and contrast agent. The simulation
gave an acoustic field of 2.5 × 32 mm at the level of −6 dB
relative to 4 MPa as shown in Fig. 3b, representing
the expected lesion region. In vivo results for the
parametric acoustic pressure amplitude cases 2.0 (G),
2.8 (H), and 4.0 MPa (D) are illustrated in Fig. 6
using boxplots. Frequently, the axial dimension was
limited by the thickness of the myocardium with the
therapy beam penetrating the left ventricle entirely
before the pressure amplitude fell below the threshold pL.
Fig. 3 Therapeutic ultrasound transducer field simulation. a FIELD II simulation of pressure distribution for free field single-element therapy transducer.
b Lesion formation based on the lesion-pressure dependence; volume narrows the region of lesion formation to where peak negative pressure is
above 2 MPa, i.e., greater than the lesion formation pressure threshold. The acoustic pressure field representing the expected lesion
region is 2.5 × 32 mm at the level of −6 dB relative to 4 MPa
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Likewise, the therapy beam pressure rose above pL before
entering the myocardium. Therefore, an increase in pres-
sure at the focus will only show limited increase in the
axial lesion size. Radial macrolesion expansion is hyper-
linear and follows the prediction of the simulation shown
as the plotted curve in Fig. 6c. Simulations were done to
compute the average radius of the acoustic beam above
the hypothesized threshold pL (2.0 MPa).
Microlesion characteristics
The spatial variation in lesion density was analyzed with
respect to the therapeutic beam geometry. Specifically,
lesion density was plotted as a function of local pressure
amplitudes. Reslicing of the therapeutic beam volume
was facilitated by placing axially oriented disks. Stacking
them along the therapeutic beam as illustrated in Fig. 5
in green, allowed for plotting of lesion density as a function
of local in situ pressure amplitudes. Least square fitting
shown as a blue line in Fig. 7a resulted in y = 4.52x − 4.07,
with 0 % lesion density occurring at 0.9 MPa indicated by
the red circle. The microlesion volumes for resliced disks
versus different acoustic amplitudes are plotted in Fig. 7b
with least square fitting resulting in y = 57.2x − 130.0 and
zero microlesion volume occurring at 2.3 MPa indicated
by the red circle.
Contrast agent availability versus macrolesion characteristics
As alluded to in the previous section, macrolesion dimen-
sions are dictated by several experimental conditions, in-
cluding contrast agent availability. More available agent
will likely generate more lesions. On the other hand, more
contrast agent per unit time may lead to agent-induced
acoustic shadowing and a diminished in situ pressure
wave amplitude. Results for changes in contrast agent
availability are shown next.
Infusion duration
At first, a constant infusion rate of 5 μL/kg/min was
tested for three infusion durations, namely 30, 100, and
300 s, for groups J, I, and D, respectively. Under ultra-
sound exposure, increase in contrast infusion time allows
for higher deposition of total number of microbubbles.
Figure 8 shows a positively correlated number of gener-
ated lesions for the respective total infusion duration.
Differences in visual score and microlesion volume for du-
rations of 30 and 100 s are not statistically different. How-
ever, a 300-s infusion duration shows a significant increase
relative to the former two conditions with respect to the
characterized microlesion volume. Specifically, the micro-
lesion volume that increases from 10, to 30, to 300 s is not
linear and will be addressed in the “Discussion” section.
Infusion rate
Here, a constant total dose of contrast agent (25 μL/kg)
was tested for two infusion rates, namely 5 μL/kg/min
for 5 min and 12.5 μL/kg/min for 2 min, for groups D
and E, respectively. A higher infusion rate, i.e., more
agent per unit time, may lead to agent-induced acoustic
shadowing and a diminished in situ wave pressure amp-
litude. Figure 9 shows no significantly different number
Fig. 4 Scatter plot showing comparison of visual score versus auto
score. The auto score was obtained from a computer-aided method
[14] with piece-wise least square fitting at a break point for the auto
score equal to 15,000. Visual scoring correlates best with auto scoring
for fewer lesion counts, which reveals the difficulty to assess large
number of lesions quantitatively by visual means
Fig. 5 Diagram illustrating a macrolesion as characterized from a
stack of histology slices. The heart wall (HW) is depicted in red lines.
A cross section of the heart is shown as a histological slice (HS),
stained with Evans blue indicating cell necrosis, i.e., microlesions. The
ultrasound (US) beam is indicated as a blue line and arrow and was
derived from least square fitting of microlesions. Along the beam, the
shown green cylindrical disks were characterized from cylindrical volume
elements that contain 95 % of the local microlesions. These coaxially
stacked disks form a radially symmetric volume, called the macrolesion
(ML), which is assumed to correlate with the in situ acoustic field
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of generated lesions for the respective infusion rates.
Note that microlesion volume here refers to the total
volume of all induced microlesions over the entire myo-
cardium, which is not identical to the shown microlesion
volume within the characterized macrolesion (macrole-
sion volume times lesion density).
Therapy beam sweeping
In this experiment, Gaussian modulation was employed
to mimic therapy beam sweeping. It was observed as
shown in Fig. 10 that both the resulting macrolesion
volume as well as the microlesion density inside the cre-
ated macrolesion is reduced in comparison to the static
beam, but not significantly different. The median macro-
lesion volumes resulting from square and Gaussian
modulations are 65.6 and 40.3 μL respectively, and the
median lesion densities are 16.8 and 14.4 %.
The pulse modulation groups corresponding to square
and Gaussian profile are shown in Fig. 2. In the
simulation modeling, the volume exposed by negative
pressures greater than 2 MPa, and marked by circles,
were integrated across space and time yielding 4.5 and
2.7 μL·s for square and Gaussian modulations, respectively.
Discussion
The quantitative results generated by the previously de-
veloped and here tested computer-aided scheme provide
possibilities for numeric and quantitative 3D lesion ana-
lysis and their dependence on experimental parameters
that were investigated for their relevance for developing
and improving MCET.
Cardiomyocyte scoring
Visual lesion counting, as a traditional evaluation
method, is appropriate for low lesion count cases as dis-
cussed for Fig. 4. However, for therapeutic applications,
a large number of lesions require tedious counting. The
computer-aided scheme [14] provides for an objective
Fig. 6 Treatment impact for different acoustic pressures. Here included a macrolesion volume, b length of macrolesion, and c radius of macrolesion
for groups exposed under 2.0 MPa (G), 2.8 MPa (H), and 4.0 MPa (D). Simulations were done for a mean radius of acoustic field above the lesion
formation pressure threshold of 2.0 MPa (PRPA). Macrolesion volumes appear positively related to acoustic pressure, where contributions come from
the radial direction while the axial sizes are insignificantly different
Fig. 7 Treatment impact characterized for re-sliced volume along therapeutic beam. Results for exposures of 2.0, 2.8, and 4.0 MPa PRPA are shown
for a scatter plot of lesion density with least square fitting and zero crossing 0.9 MPa PRPA and b scatter plot of microlesion volume with least
square fitting and zero crossing 2.3 MPa PRPA
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and quantitative lesion analysis. As shown in Fig. 4, a
dramatic change in visual score versus auto score for
high-count cases opposed to low-count cases reveals the
limitation of visual scoring, when counting large num-
bers of lesions. Machine-operated and tested algorithms
prevail. Note that even at low counts, auto score has a
positively correlated relationship to visual score but does
not have a one-to-one correspondence. Variance arises
from manual bias differentiating individual cells from a
clustered cell pool. On the other side as for auto scoring,
imperfection exists when a constant conversion factor is
employed for converting microlesion area, i.e., image
pixels, on a given histology slide to a fixed number of
cells, Eq. 1. An additional limitation is the assumption
that cells possessing the same dimensions for each heart
layer but different orientations for three layers [14]. Our
model uses a statistical average based on a standard
heart. This might lead to partial violations when the
actual geometry (Fig. 11a) differs from the standard
heart (Fig. 11b).
Experimental perturbations exclusions
Initially, the choice of injections sites, i.e., the jugular vein
versus the tail vein, were thought to possibly influence the
number of systemically circulating microbubbles. Compar-
ing the two cohorts, however, showed that the two micro-
bubble administration routes were equivalent. As shown
in Fig. 12, tail vein (a) versus jugular vein (b) injection did
not lead to significant differences in the subsequent lesion
formation in either lesion density or in macrolesion vol-
ume. Additionally, variations of transducer aiming were
tested. Intentionally aiming the ultrasound at the ribs
(Group C) does not impact the therapeutic result. In vivo
variations can be significant (see error bars in Fig. 12);
however, there is a significant overlap between the tested
routes for injection and between various aiming paths.
Fig. 8 Treatment impact for different contrast agent infusion duration. Results for a visual score and b microlesion volume for groups infused
with contrast agents for 30, 100, and 300 s, at a rate of 5 μL/kg/min, for groups J, I, and D, respectively. A positively correlated number of generated
lesions are seen for the respective total infusion duration. Differences in visual score and microlesion volume for durations of 30 and 100 s are not
statistically different. However, an infusion duration of 300 s significantly differs from the former two conditions
Fig. 9 Treatment impact for different contrast agent infusion rates. Results are shown for a microlesion volume, b macrolesion volume, and c lesion
density for groups infused with contrast agents for 5 min at a rate of 5 μL/kg/min (D) and 2 min at 12.5 μL/kg/min (E), i.e., yielding the same total
dose. They are not significantly different, showing that the impact is dominated by the cumulative dose
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Acoustic field modeling
Acoustic amplitude
Acoustic modeling provides a way to approximate lesion
formation. In the therapy, impact analysis bioeffects of
various acoustic exposures were investigated. The associ-
ated field simulation underestimates the mean radius of
the macrolesion at 4 MPa as shown in Fig. 6c. This is
because in vivo, some of the beam penetrates the left
ventricle. This part of the beam was not excluded in the
simulation; thus, the simulation resulted in averaging
out the affected macrolesion radius. Another factor
contributing to the greater treatment effect seen in
vivo than the simulation comes from deformation of
hearts after being harvested. Rats were treated at the
ends of systole but hearts were relaxed after being
sacrificed. Thus, the acoustic pattern may be distorted
to some extent.
Swept beam
Treatment in humans will require focusing of the thera-
peutic beam at a larger area than currently done in ro-
dents (rats). Such will either lead to the need of a
modified, i.e., larger, point spread function or more likely
numerous repetitions of individual exposures. The latter
can be realized by either individual focal treatments or
by employing a swept beam. The former will require a
longer time for treatment of an equivalent total count of
focal spots since the beam will be stepped from treat-
ment location n to n + 1; therefore, a swept beam was
investigated. Illustrated by “O” plot marks in Fig. 2 are
Fig. 10 Treatment impact for square and Gaussian pulse modulation schemes. Results for the impact of individual focal treatment (group B) versus a
swept beam (group D) are shown for a the corresponding macrolesion volume and b the observed lesion density. Similar impact is seen between
Gaussian modulation and square modulation, which validates that a swept beam scheme might be a viable method to shorten treatment duration
Fig. 11 Example microscopic brightfield images of treated heart slices. The histology slice a contains sparse microlesions. Note that microlesions
appear with a light blue stained by Evans blue. The shown histology violates the standard heart model shown in b. Distributed myocytes are lying in
different tissue layers and with varying orientations
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the individual tone bursts that exceed the lesion forma-
tion pressure threshold. With that and the previously
mentioned axisymmetric rotational model (point spread
function), an effective treatment volume was simulated.
Integration across space and time, yielded 4.5 and 2.7 μL·s
for square and Gaussian modulations, respectively. There-
fore, the swept beam simulation predicts an effective vol-
ume of 59.8 % of that of an individual focal treatment.
The experimental macrolesion volume shown in Fig. 10a
yields an effective median volume fraction of 61.5 %,
supporting the axisymmetric rotational volumetric model.
Thresholded induced and statistically accumulated lesion
Lesion formation as accumulated statistical events
In the experiment of increasing infusion, the slightly
decreasing trend of lesion density shown in Fig. 6 may
indicate some shadowing effect caused by a large
population of instantaneous microbubbles placed along
the beam path, acting as scatterers. However, the sha-
dowing factor will need to be verified for the cases of a
longer path, such as in a larger animal model.
The experiment of various infusion durations of
contrast agents is potentially equivalent with longer dur-
ation exposure. As shown in Fig. 13, visual score, micro-
lesion volume, macrolesion volume, and mean radius of
macrolesion show positive correlation revealing the fact
that the probability to create lesion is accumulated over
time. Growth of the macrolesion radius indicates that
the edge of the macrolesion is contributing to the lesion
formation over time. Lesion density increases for longer
infusion times. Short term and intermediate do not sig-
nificantly differ. This could be due to the lack of statis-
tical power or too short of a duration to allow for fully
developed statistical analysis. The macrolesion lengths
Fig. 12 Comparison of treatment impact for different injections sites and ultrasound aiming strategies. Results show a macrolesion volume b and
lesion density for two microbubble administration routes, i.e., tail vein (A) versus jugular vein (B) injection; additionally shown are c macrolesion
volume and d lesion density for regular aiming (B) and intentionally aiming at the ribs (C). Injection and aiming variations do not significantly
differ among the tested groups
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are not showing any strong correlation with the infusion
interval, as they are likely limited by the distal ventricle
and possibly due to tissue attenuation.
Microlesion density versus ultrasound amplitude
Least square fitting in Fig. 7a implies that an increasing
acoustic pressure has a positive effect on microlesion
formation up to 4 MPa, i.e., higher acoustic pressure or
exposure possesses the higher potential to induce bioef-
fects. A similar positive correlation of acoustic amplitude
on cavitation-induced bioeffects was also presented by
Samuel et al. [18]. One possible reason is that larger
pressure will result in a larger active microbubble popu-
lation. Therefore, a larger density of microlesion will be
induced by the then more frequent microbubble cavita-
tion events. For a constant pressure amplitude, macrole-
sions also grow radially over time. This is because of the
probabilistic accumulation of microlesions on the pen-
umbra of the current macrolesion. There, the probability
χ for microlesion generation is larger than 0 % and
smaller than 100 %, i.e., the sound pressure amplitude is
close to the threshold pL discussed above. If χ is 20 %,
then a five times longer exposure will statistically result
in additional lesion formation.
Acoustic pressure threshold
The zero microlesion volume shown in the line fit in
Fig. 7b might overestimate the acoustic pressure thresh-
old for lesion induction. This is because microlesion
volumes were characterized in a way that could bias to-
wards beam regions with lower acoustic pressure and
hence lower partial microlesion volume.
Additionally, the acoustic pressure threshold for micro-
lesion induction by either lesion densities or microlesion
volumes is a rough estimation and may be inaccurate due
to biological variations, with R2 being 0.48 and 0.56.
Application in human
Ideally, the wanted axial length of the transducer’s point
spread function matches the myocardial thickness. Here
in the presented small animal model, a shorter depth of
field would have been desirable, though no side effects,
except for some pulmonary hemorrhaging, presented in
the study. The characterized macrolesions for all rats
Fig. 13 Scatter plot of characterized parameters versus infusion durations. Results for (a) visual score, (b) microlesion volume, (c) macrolesion
volume, and (d) macrolesion mean radius show some linear dependence with respect to infusion duration, revealing the fact that the
probability to create lesion is accumulative over time. Growth of the macrolesion radius (e) indicates that the macrolesion edges contribute
to the lesion formation as well
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showed similar lengths, which in most cases here is due
to the acoustic path restrained by the limited thickness
of the left vertical wall. However, when the study moves
to a larger animal model (such as swine) rather than
the currently employed rodents (rats), the effect of
therapeutic pressure on the macrolesion length will
manifest itself and be vital for lesion formation and
accretion.
The shown results serve as a preliminary test of
MCET for application in humans. The main benefit from
this therapy method is the minimal invasiveness and the
hypothesis that cavitation-induced, sparsely distributed
microlesions do not lead to major infarct-like scars,
which can disrupt conduction pathways and lead to
heart block, such as for alcohol ablation treatment [19].
The relationship between lesion characteristics from the
small animal model, such as lesion dimension and dens-
ity and in situ ultrasound field, is assumed to be analo-
gous to that of a large animal model. Both models follow
the same rationale of lesion formation. In the larger
model, especially in humans, it is anticipated that we will
have to create composite lesions, i.e., lesions created by
electronically and/or mechanically sweeping the beam.
For therapy of large volumes, the therapy beam will
likely be scanned through the desired volume (simulated
here by the Gaussian modulation) to accomplish the
treatment in less time than is needed to treat point by
point (as in HIFU). Suppose a human subject needs
MCET treatment at a myocardial region of 4 cm
diameter [20]. Assuming that the left ventricular wall of
the hypertrophic heart has a 21-mm thickness [2], a
macrolesion, approximated as a cylinder, with volume
π × (4 cm/2)2 × 21 mm = 26.4 mL, would be needed. As-
suming that the therapy employs the recommended dose
of Definity® for diagnostic exams, i.e., 5 μL/kg/min, a
5-min treatment of a single focal spot will yield a 50-μL
macrolesion with 20 % microlesion density. To create the
aforementioned macrolesion, a total duration of approxi-
mately 2640 min will be needed to achieve the desired le-
sion volume. Recruitment of a swept beam to foster the
lateral lesion formation at 56 fps, as discussed above, will
reduce the total duration to 47 min. Stacking multiple
axial focal zones will enlarge axial lesion size and further
accelerate the therapy. The above calculations are under
the assumption that the in vivo microbubble distribution
in the myocardium is similar in human and the chosen rat
model. A large animal model for human cardiophysiology,
such as swine, will be needed for investigating the clinical
transition for MCET.
Conclusion
The quantitative scoring scheme overcomes the limitation
of traditional visual scoring and works for histological
cases with a large lesion count, i.e., has an appropriate
dynamic range for evaluating therapeutic applications.
The presented results have shown that MCET-induced
macrolesions grow radially as the acoustic pressure ampli-
tude increases. A swept beam as a new method to shorten
treatment time seems promising but requires additional
verification to ensure efficacy. These characterizations and
validations may assist future MCET treatment planning.
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